Hoth Therapeutics Stock Price, News & Analysis (NASDAQ:HOTH)

-0.21 (-4.56 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
Now: $4.40
50-Day Range
MA: $5.21
52-Week Range
Now: $4.40
Volume27,300 shs
Average Volume7,205 shs
Market Capitalization$44.35 million
P/E RatioN/A
Dividend YieldN/A
Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HOTH



Sales & Book Value

Annual SalesN/A



Market Cap$44.35 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.

Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics Inc (NASDAQ:HOTH) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. View Hoth Therapeutics' Earnings History.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Hoth Therapeutics.

What price target have analysts set for HOTH?

1 brokerages have issued 1-year target prices for Hoth Therapeutics' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.

What is the consensus analysts' recommendation for Hoth Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.

Has Hoth Therapeutics been receiving favorable news coverage?

News articles about HOTH stock have been trending negative on Saturday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hoth Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Hoth Therapeutics.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totalling 18,300 shares, a decrease of 7.6% from the July 31st total of 19,800 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is currently 0.9 days. Currently, 0.6% of the company's stock are sold short. View Hoth Therapeutics' Current Options Chain.

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include ADMA Biologics (ADMA), Ekso Bionics (EKSO), Opko Health (OPK), Valeritas (VLRX), Snap (SNAP), Aeglea Bio Therapeutics (AGLE), Aqua Metals (AQMS), Baidu (BIDU), ContraFect (CFRX) and CHF Solutions (CHFS).

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the folowing people:
  • Mr. Robb Knie, Pres, CEO & Director (Age 50)
  • Mr. David S. Briones, Chief Financial Officer (Age 43)
  • Ms. Jane H. Behrmann, VP of Operations (Age 34)

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

When did Hoth Therapeutics' lock-up period expire?

Hoth Therapeutics' lock-up period expired on Wednesday, August 14th. Hoth Therapeutics had issued 1,250,000 shares in its IPO on February 15th. The total size of the offering was $7,000,000 based on an initial share price of $5.60. Since the expiration of Hoth Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $4.40.

How big of a company is Hoth Therapeutics?

Hoth Therapeutics has a market capitalization of $44.35 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]

MarketBeat Community Rating for Hoth Therapeutics (NASDAQ HOTH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about Hoth Therapeutics and other stocks. Vote "Outperform" if you believe HOTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by Staff

Featured Article: Systematic Risk

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel